Peplin maintains clinical trial ambitions

By Renate Krelle
Wednesday, 09 February, 2005

Peplin Biotech's (ASX:PEP) half-year results have revealed a AUD$13 million cash balance -- enough, the company says, to complete three Phase II clinical trials of its skin cancer treatment PEP005.

Just over $9.5 million of the balance came from a share issue to existing shareholders and institutions in December. The figures also show a final AUD$1.8 million termination payment from its collaboration with US company Allergan. Research and development expenses during the period rose $0.9 million, in line with increased product development activities, to $6.2 million. Peplin's net loss before and after tax was $4.1 million compared with a net loss of $3.9 million for the corresponding period last year.

After a discouraging second-half of 2004, during which Allergan handed back the rights to PEP005's development, Peplin was boosted recently by a Phase I safety and tolerability trial for PEP005. In 40 per cent of cases, a single application of its PEP005 topical gel for pre-cancerous skin 'sunspots' completely or substantially cleared the volunteers' actinic keratoses (AK), compared with 15 per cent for placebo patients.

"The positive Phase I trial results fundamentally validate our decision late last year to reacquire the product rights and to take forward the clinical trial program on our own," said CEO Michael Aldridge.

Related News

'Low-risk' antibiotic linked to rise of dangerous superbug

A new study has challenged the long-held belief that rifaximin — commonly prescribed to...

Robotic hand helps cultivate baby corals for reef restoration

The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...

Stem cell experiments conducted in space

Scientists are one step closer to manufacturing stem cells in space — which could speed up...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd